Zobrazeno 1 - 10
of 32
pro vyhledávání: '"Mary Beth Riley"'
Autor:
Lynn M. Rundhaugen, Chadi Nabhan, Mary Beth Riley, Simrit Parmar, John L. Frater, Adekunle Raji, Martin S. Tallman, Larry Boehlke
Publikováno v:
Leukemia Research. 28:909-919
The prognosis for patients with relapsed/refractory AML, secondary leukemia and AML in older adults is extremely poor. An appealing alternative approach to intensive cytotoxic chemotherapy is to induce apoptosis with a novel agent. There is in vitro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c71ce3b0bd42d7dcdec53c5a85aa8a43
https://doi.org/10.1016/j.leukres.2003.12.012
https://doi.org/10.1016/j.leukres.2003.12.012
Autor:
L. C. Peterson, Martin S. Tallman, Mary Beth Riley, Larry Boehlke, Chadi Nabhan, M. Jatoi, Lynn M. Rundhaugen
Publikováno v:
Annals of Oncology. 15:1231-1236
Background: Gemtuzumab ozogamicin (GO) is approved for the treatment of older adults with acute myeloid leukemia in first relapse. Several reports have suggested an association between GO administration and hepatic veno-occlusive disease (VOD), which
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::77fc3181749ac0c09d15b6fcd2de939f
https://doi.org/10.1093/annonc/mdh324
https://doi.org/10.1093/annonc/mdh324
Autor:
Leo I. Gordon, Mary Beth Riley
Publikováno v:
Seminars in Oncology Nursing. 20:8-13
Objectives To detail recent developments pertaining to the efficacy and safety of radioimmunotherapy with yttrium 90 ( 90 Y) ibritumomab tiuxetan for patients with B-cell non-Hodgkin’s lymphoma (NHL). Data sources Published clinical trials of 90 Y
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f24f54c44a2a709d23190fce27b67a31
https://doi.org/10.1053/j.soncn.2004.02.008
https://doi.org/10.1053/j.soncn.2004.02.008
Autor:
Steven T. Rosen, Martin S. Tallman, Timothy M. Kuzel, Leo I. Gordon, David Patton, Chadi Nabhan, Mary Beth Riley
Publikováno v:
Leukemia & Lymphoma. 45:2269-2273
The treatment of patients with chronic lymphocytic leukemia (CLL) who fail purine analogues is sub optimal. CLL lymphocytes express two antigens, namely CD 20 and CD 52, for which monoclonal antibodies are readily available. Rituximab is a chimeric m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3853fdc9104224b91c053d449cac8a42
https://doi.org/10.1080/10428190412331286096
https://doi.org/10.1080/10428190412331286096
Autor:
Mary Beth Riley, John L. Frater, Martin S. Tallman, Mary Ann Hrisinko, Debra Resta, Brian J. Druker, Daina Variakojis, LoAnn Peterson
Publikováno v:
American Journal of Clinical Pathology. 119:833-841
We evaluated bone marrow pathologic features and cytogenetic and molecular genetic status of 13 patients with interferon-resistant, chronic-phase chronic myeloid leukemia (CML), treated with imatinib mesylate (Gleevec). All had morphologic evidence o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6af6135fe8942ef3bf68dcafc1d8077d
https://doi.org/10.1309/a4rgp4lf12ggh8mw
https://doi.org/10.1309/a4rgp4lf12ggh8mw
Autor:
Mary Beth Riley, Stephanie A. Gregory, Raywin Huang, Ahmad Jajeh, Homayoun Shahidi, Sari H. Enschede, Parameswaran Venugopal, Harvey D. Preisler
Publikováno v:
Leukemia & Lymphoma. 40:325-334
Interferon-alfa in combination with cytotoxic chemotherapy has been shown to be effective in treating certain types of non-Hodgkin's lymphoma (NHL) (1). However, there is no published data on upfront induction treatment of aggressive NHL with IFN-alf
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::91824134b77b89502ef204a306c7fb85
https://doi.org/10.3109/10428190109057931
https://doi.org/10.3109/10428190109057931
Autor:
Katherine L. Byar, Mary Beth Riley
Publikováno v:
Seminars in oncology nursing. 20(1 Suppl 1)
Objectives To present the rationale for and development of radioimmunotherapy (RIT) for non-Hodgkin's lymphoma (NHL), which culminated in the FDA's approval of yttrium 90 ( 90 Y) ibritumomab tiuxetan in February 2002. Data sources Published clinical
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::72b7daee6b3af80a66846702330c5d67
https://pubmed.ncbi.nlm.nih.gov/15160855
https://pubmed.ncbi.nlm.nih.gov/15160855
Autor:
Alfred Rademaker, Lynn M. Rundhaugen, Mashal Jatoi, Martin S. Tallman, Larry Boehlke, Chadi Nabhan, Mary Beth Riley
Publikováno v:
Leukemia research. 29(1)
The prognosis of acute myeloid leukemia (AML) in older adults is generally poor. Standard cytotoxic chemotherapy is usually poorly tolerated and provides dismal results in this patient population. Gemtuzumab ozogamicin (GO) is an immunoconjugate that
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::69edc80bc3799099e65475b34a581529
https://pubmed.ncbi.nlm.nih.gov/15541475
https://pubmed.ncbi.nlm.nih.gov/15541475
Autor:
John L, Frater, Martin S, Tallman, Daina, Variakojis, Brian J, Druker, Debra, Resta, Mary Beth, Riley, Mary Ann, Hrisinko, LoAnn C, Peterson
Publikováno v:
American journal of clinical pathology. 119(6)
We evaluated bone marrow pathologic features and cytogenetic and molecular genetic status of 13 patients with interferon-resistant, chronic-phase chronic myeloid leukemia (CML), treated with imatinib mesylate (Gleevec). All had morphologic evidence o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::9a29e4453646421fe7a5e6eebc9db240
https://pubmed.ncbi.nlm.nih.gov/12817431
https://pubmed.ncbi.nlm.nih.gov/12817431
Autor:
Mary Beth, Riley
Publikováno v:
Clinical journal of oncology nursing. 7(1)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::d47d941559e40db21f407afa0cee9595
https://pubmed.ncbi.nlm.nih.gov/12629947
https://pubmed.ncbi.nlm.nih.gov/12629947